------------------ | ------------------ | --------------- |
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |
Emerging Growth Company |
Date: October 23, 2019 | ALEXION PHARMACEUTICALS, INC. |
By: /s/ Doug Barry | |
Name: Doug Barry | |
Title: Vice President, Corporate Law | |
• | 3Q19 total revenues of $1,263.1 million, a 23 percent increase over 3Q18 and a 23 percent volume increase |
• | 3Q19 GAAP diluted EPS of $2.08; non-GAAP diluted EPS of $2.79 |
• | Received 2 recent regulatory approvals - ULTOMIRIS® (ravulizumab-cwvz) for atypical hemolytic uremic syndrome (aHUS) in the U.S. and SOLIRIS® (eculizumab) for adults with neuromyelitis optica spectrum disorder (NMOSD) in the EU |
• | Announced agreement to acquire Achillion Pharmaceuticals |
• | Continued disciplined business development execution with Eidos and Stealth BioTherapeutics collaborations |
• | Increased revenues and EPS guidance to reflect strong business and continued growth |
• | Total net product sales were $1,263.1 million in the third quarter of 2019, compared to $1,026.5 million in the third quarter of 2018. |
• | SOLIRIS® (eculizumab) net product sales were $990.5 million, compared to $888.0 million in the third quarter of 2018, representing a 12 percent increase. SOLIRIS volume increased 11 percent year-over-year. |
• | ULTOMIRIS® (ravulizumab-cwvz) net product sales were $89.9 million in the third quarter of 2019. |
• | STRENSIQ® (asfotase alfa) net product sales were $154.3 million, compared to $113.2 million in the third quarter of 2018, representing a 36 percent increase. STRENSIQ volume increased 36 percent year-over-year. |
• | KANUMA® (sebelipase alfa) net product sales were $28.4 million, compared to $25.3 million in the third quarter of 2018, representing a 12 percent increase. KANUMA volume increased 16 percent year-over-year. |
• | GAAP cost of sales was $95.2 million, compared to $90.6 million in the third quarter of 2018. Non-GAAP cost of sales was $91.8 million, compared to $87.3 million in the third quarter of 2018. |
• | GAAP R&D expense was $232.9 million, compared to $174.8 million in the third quarter of 2018. Non-GAAP R&D expense was $186.1 million, compared to $162.3 million in the third quarter of 2018. |
• | GAAP SG&A expense was $299.3 million, compared to $258.7 million in the third quarter of 2018. Non-GAAP SG&A expense was $260.4 million, compared to $224.5 million in the third quarter of 2018. |
• | GAAP income tax expense was $67.9 million, compared to $11.2 million in the third quarter of 2018. Non-GAAP income tax expense was $82.5 million, compared to $75.8 million in the third quarter of 2018. |
• | GAAP diluted EPS was $2.08, compared to $1.47 in the third quarter of 2018. Non-GAAP diluted EPS was $2.79, compared to $2.02 in the third quarter of 2018. |
• | SOLIRIS - Neuromyelitis Optica Spectrum Disorder (NMOSD): In August 2019, the European Commission approved SOLIRIS for adults with anti-aquaporin-4 (AQP4) auto antibody-positive NMOSD. An application for approval in Japan is under review. Alexion plans to initiate a Phase 3 study in children and adolescents with NMOSD by the end of 2019. |
• | SOLIRIS - Generalized Myasthenia Gravis (gMG): A Phase 3 study of SOLIRIS in children and adolescents with gMG is underway. |
• | ULTOMIRIS - Paroxysmal Nocturnal Hemoglobinuria (PNH): A Phase 3 study of ULTOMIRIS in children and adolescents with PNH is underway. |
• | ULTOMIRIS - Atypical Hemolytic Uremic Syndrome (aHUS): In October 2019, the U.S. Food and Drug Administration (FDA) approved ULTOMIRIS for the treatment of aHUS to inhibit complement-mediated thrombotic microangiopathy (TMA) for adults and children one month and older. Applications for approval in the EU and Japan are under review. A Phase 3 study of ULTOMIRIS in children and adolescents with aHUS is underway. |
• | ULTOMIRIS - Subcutaneous: A single, PK-based Phase 3 study of ULTOMIRIS delivered subcutaneously once per week is underway to support registration in PNH and aHUS. Data are expected in the first half of 2020. |
• | ULTOMIRIS - gMG: A Phase 3 study of ULTOMIRIS in adults with gMG is underway. |
• | ULTOMIRIS - NMOSD: Alexion plans to initiate a Phase 3 study of ULTOMIRIS in NMOSD by the end of 2019. |
• | ULTOMIRIS - Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA): Alexion plans to initiate a Phase 3 study of ULTOMIRIS in HSCT-TMA in the first half of 2020, pending regulatory feedback. |
• | ULTOMIRIS - Amyotrophic Lateral Sclerosis (ALS): Alexion plans to initiate a Phase 2/3 study for ULTOMIRIS in ALS in early 2020, pending regulatory feedback. |
• | ALXN1840 (WTX101) - Wilson Disease: A Phase 3 study of ALXN1840 (WTX101) in Wilson disease is underway. Enrollment is expected to complete in early 2020. |
• | CAEL-101 - Caelum Biosciences: Alexion is collaborating with Caelum Biosciences to develop CAEL-101 for light chain (AL) amyloidosis, a rare systemic disorder that causes misfolded immunoglobulin light chain protein to build up in and around tissues, resulting in progressive and widespread organ damage. A pivotal Phase 2/3 study investigating CAEL-101 as an add-on to current standard-of-care therapy is planned to begin in the first half of 2020. In October 2019, the European Commission granted orphan drug designation to CAEL-101 for the treatment of AL amyloidosis. |
• | AG10 - Eidos: In September 2019, Alexion announced an agreement with Eidos for an exclusive license to develop and commercialize AG10 in Japan. AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR) – destabilized and misfolded transthyretin (TTR) protein – by binding and stabilizing TTR in the blood. Eidos is currently evaluating AG10 in a Phase 3 study in the U.S. and Europe for ATTR cardiomyopathy (ATTR-CM) – a progressive, fatal disease caused by the accumulation of misfolded TTR amyloid in the heart – and plans to begin a Phase 3 study in ATTR polyneuropathy (ATTR-PN) – a progressive, fatal disease caused by the accumulation of misfolded TTR amyloid in the peripheral nervous system. Alexion plans to expand the AG10 program into Japan in 2020, pending regulatory feedback. |
• | Elamipretide - Stealth: In October 2019, Alexion announced an agreement with Stealth BioTherapeutics for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) - a genetic mitochondrial disease - elamipretide is a novel, potential first-in-class therapy that targets mitochondrial dysfunction. Alexion will have the opportunity to exercise the option following the delivery of results from the Phase 3 PMM study, which are expected in the first quarter of 2020. If exercised, the option also provides for co-development and commercialization of elamipretide in Barth syndrome, Leber’s hereditary optic neuropathy (LHON) and geographic atrophy associated with dry age-related macular degeneration (GA). |
• | ALXN1830 (SYNT001): Alexion plans to initiate a Phase 2 study of ALXN1830 (SYNT001) in warm autoimmune hemolytic anemia (WAIHA) in early 2020. In addition, Alexion plans to initiate a Phase 1 study of a subcutaneous formulation of ALXN1830 in healthy volunteers in early 2020. Pending |
• | Danicopan (ACH-4471) & ACH-5228 - Achillion: In October 2019, Alexion announced an agreement to acquire Achillion. Pending approval of Achillion shareholders, satisfaction of customary closing conditions and approval from relevant regulatory agencies, including clearance under the HSR Act, the acquisition is expected to close in the first half of 2020. The acquisition will add two oral Factor D inhibitors to treat rare diseases associated with the complement alternative pathway to Alexion's clinical-stage pipeline - danicopan (ACH-4471) and ACH-5228. Danicopan is currently in Phase 2 development as an add-on therapy to eculizumab for PNH in patients with clinical extravascular hemolysis (EVH) and for C3 glomerulopathy, and ACH-5228 is currently in Phase 1 development. |
• | ULTOMIRIS - Primary Progressive Multiple Sclerosis (PPMS): Alexion plans to initiate an exploratory clinical study of ULTOMIRIS in PPMS. |
• | ALXN1810 - Subcutaneous: Alexion has completed a Phase 1 study of subcutaneous ALXN1210 co-administered with Halozyme's ENHANZE® drug-delivery technology, recombinant human hyaluronidase enzyme (rHuPH20), a next-generation subcutaneous formulation called ALXN1810. Strategic planning for the best development path for ALXN1810 is ongoing. |
• | Affibody AB - ABY-039: Alexion is partnering with Affibody AB to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn). |
• | ALXN1720: In September 2019, Alexion began a Phase 1 study of ALXN1720, a novel anti-C5 albumin-binding bi-specific mini-body that binds and prevents activation of human C5, in healthy volunteers. |
• | Zealand Pharma A/S: Alexion is collaborating with Zealand Pharma A/S to discover and develop novel peptide therapies for up to four targets in the complement pathway. Peptides offer a number of advantages, including being highly selective and potent, allowing low dosage volumes for ease of administration, and having the potential to treat a broad range of complement-mediated diseases. |
• | Dicerna - GalXCTM : Alexion is collaborating with Dicerna Pharmaceuticals to jointly discover and develop up to four subcutaneously delivered GalXCTM RNA interference (RNAi) candidates, currently in pre-clinical development, for the treatment of complement-mediated diseases. |
• | Complement Pharma - CP010: Alexion is collaborating with Complement Pharma to co-develop CP010, a pre-clinical C6 inhibitor that has the potential to treat multiple neurological disorders. |
• | Immune Pharma - anti-eotaxin-1 antibody: Alexion has entered into an asset purchase agreement with Immune Pharma to acquire an anti-eotaxin-1 antibody for potential development in inflammatory diseases. The agreement is pending completion of bankruptcy proceedings, which are expected to conclude by the first quarter of 2020. |
Previous (as of July 24, 2019) | Updated (as of October 23, 2019) | |
Total revenues | $4,750 to $4,800 million | $4,860 to $4,890 million |
SOLIRIS/ULTOMIRIS revenues | $4,095 to $4,130 million | $4,180 to $4,200 million |
Metabolic revenues | $655 to $670 million | $680 to $690 million |
R&D (% total revenues) | ||
GAAP | 17% to 19% | 17% to 18% |
Non-GAAP | 14% to 16% | 14% to 15% |
SG&A (% total revenues) | ||
GAAP | 23% to 24% | 24% to 25% |
Non-GAAP | 20% to 21% | 21% to 22% |
Operating margin | ||
GAAP | 42% to 43% | 41% to 42% |
Non-GAAP | 55% to 56% | 55% to 56% |
Earnings per share | ||
GAAP | $8.13 to $8.41 | $8.58 to $8.78 |
Non-GAAP | $9.65 to $9.85 | $10.25 to $10.40 |
Three months ended | Nine months ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Net product sales | $ | 1,263.1 | $ | 1,026.5 | $ | 3,605.8 | $ | 3,001.6 | |||||||
Other revenue | — | — | 1.0 | 0.8 | |||||||||||
Total revenues | 1,263.1 | 1,026.5 | 3,606.8 | 3,002.4 | |||||||||||
Cost of sales | 95.2 | 90.6 | 280.2 | 277.5 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 232.9 | 174.8 | 616.4 | 524.8 | |||||||||||
Selling, general and administrative | 299.3 | 258.7 | 880.1 | 793.1 | |||||||||||
Acquired in-process research and development | — | — | (4.1 | ) | 803.7 | ||||||||||
Amortization of purchased intangible assets | 75.6 | 80.0 | 235.7 | 240.1 | |||||||||||
Change in fair value of contingent consideration | 29.8 | 53.5 | 7.2 | 110.9 | |||||||||||
Restructuring expenses | 0.3 | 10.3 | 11.9 | 26.4 | |||||||||||
Total operating expenses | 637.9 | 577.3 | 1,747.2 | 2,499.0 | |||||||||||
Operating income | 530.0 | 358.6 | 1,579.4 | 225.9 | |||||||||||
Other income and expense: | |||||||||||||||
Investment income | 23.0 | 5.9 | 50.6 | 119.4 | |||||||||||
Interest expense | (17.9 | ) | (24.6 | ) | (56.1 | ) | (73.7 | ) | |||||||
Other income and (expense) | 0.4 | 2.2 | 2.9 | 3.5 | |||||||||||
Income before income taxes | 535.5 | 342.1 | 1,576.8 | 275.1 | |||||||||||
Income tax expense | 67.9 | 11.2 | 61.5 | 152.5 | |||||||||||
Net income | $ | 467.6 | $ | 330.9 | $ | 1,515.3 | $ | 122.6 | |||||||
Earnings per common share | |||||||||||||||
Basic | $ | 2.09 | $ | 1.48 | $ | 6.77 | $ | 0.55 | |||||||
Diluted | $ | 2.08 | $ | 1.47 | $ | 6.72 | $ | 0.55 | |||||||
Shares used in computing earnings per common share | |||||||||||||||
Basic | 223.3 | 222.9 | 223.8 | 222.5 | |||||||||||
Diluted | 224.5 | 224.6 | 225.4 | 224.2 | |||||||||||
Three months ended | Nine months ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
GAAP net income | $ | 467.6 | $ | 330.9 | $ | 1,515.3 | $ | 122.6 | |||||||
Before tax adjustments: | |||||||||||||||
Cost of sales: | |||||||||||||||
Share-based compensation | 3.4 | 3.3 | 10.7 | 12.2 | |||||||||||
Restructuring related expenses (1) | — | — | — | 5.8 | |||||||||||
Research and development expense: | |||||||||||||||
Share-based compensation | 16.7 | 12.5 | 45.9 | 42.5 | |||||||||||
Upfront payments related to licenses and collaborations (2) | 30.1 | — | 76.3 | — | |||||||||||
Restructuring related expenses (1) | — | — | — | 0.1 | |||||||||||
Selling, general and administrative expense: | |||||||||||||||
Share-based compensation | 38.9 | 29.8 | 120.1 | 96.2 | |||||||||||
Restructuring related expenses (1) | — | 7.9 | — | 18.0 | |||||||||||
Litigation charges | — | — | 0.1 | 7.1 | |||||||||||
Gain on sale of asset | — | (3.5 | ) | — | (3.5 | ) | |||||||||
Acquired in-process research and development (3) | — | — | (4.1 | ) | 803.7 | ||||||||||
Amortization of purchased intangible assets | 75.6 | 80.0 | 235.7 | 240.1 | |||||||||||
Change in fair value of contingent consideration (4) | 29.8 | 53.5 | 7.2 | 110.9 | |||||||||||
Restructuring expenses (1) | 0.3 | 10.3 | 11.9 | 26.4 | |||||||||||
Investment income: | |||||||||||||||
Change in value of strategic equity investments (5) | (12.0 | ) | — | (20.6 | ) | (100.8 | ) | ||||||||
Other income: | |||||||||||||||
Restructuring related expenses (1) | — | — | — | (0.1 | ) | ||||||||||
Adjustments to income tax expense (6) | (14.6 | ) | (64.6 | ) | (212.1 | ) | (68.9 | ) | |||||||
Non-GAAP net income | $ | 635.8 | $ | 460.1 | $ | 1,786.4 | $ | 1,312.3 | |||||||
GAAP earnings per common share - diluted | $ | 2.08 | $ | 1.47 | $ | 6.72 | $ | 0.55 | |||||||
Non-GAAP earnings per common share - diluted | $ | 2.79 | $ | 2.02 | $ | 7.83 | $ | 5.78 | |||||||
Shares used in computing diluted earnings per common share (GAAP) | 224.5 | 224.6 | 225.4 | 224.2 | |||||||||||
Shares used in computing diluted earnings per common share (non-GAAP) | 227.7 | 227.4 | 228.2 | 227.0 |
Three months ended September 30, | Three months ended September 30, | ||||||||||||||||||||||||||||||
2019 | 2018 | ||||||||||||||||||||||||||||||
Employee Separation Costs | Asset-Related Charges | Other | Total | Employee Separation Costs | Asset-Related Charges | Other | Total | ||||||||||||||||||||||||
Cost of sales | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||||
Research and development | — | — | — | — | — | — | — | — | |||||||||||||||||||||||
Selling, general and administrative | — | — | — | — | — | 7.9 | — | 7.9 | |||||||||||||||||||||||
Restructuring expense | (2.8 | ) | — | 3.1 | 0.3 | 2.8 | — | 7.5 | 10.3 | ||||||||||||||||||||||
Other (income) expense | — | — | — | — | — | — | — | — | |||||||||||||||||||||||
$ | (2.8 | ) | $ | — | $ | 3.1 | $ | 0.3 | $ | 2.8 | $ | 7.9 | $ | 7.5 | $ | 18.2 |
Nine months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||
2019 | 2018 | ||||||||||||||||||||||||||||||
Employee Separation Costs | Asset-Related Charges | Other | Total | Employee Separation Costs | Asset-Related Charges | Other | Total | ||||||||||||||||||||||||
Cost of sales | $ | — | $ | — | $ | — | $ | — | $ | — | $ | 5.8 | $ | — | $ | 5.8 | |||||||||||||||
Research and development | — | — | — | — | — | 0.1 | — | 0.1 | |||||||||||||||||||||||
Selling, general and administrative | — | — | — | — | — | 18.0 | — | 18.0 | |||||||||||||||||||||||
Restructuring expense | 8.7 | — | 3.2 | 11.9 | 6.9 | — | 19.5 | 26.4 | |||||||||||||||||||||||
Other (income) expense | — | — | — | — | — | — | (0.1 | ) | (0.1 | ) | |||||||||||||||||||||
$ | 8.7 | $ | — | $ | 3.2 | $ | 11.9 | $ | 6.9 | $ | 23.9 | $ | 19.4 | $ | 50.2 |
Twelve months ending | ||||||||
December 31, 2019 | ||||||||
Low | High | |||||||
GAAP net income | $ | 1,926 | $ | 1,970 | ||||
Before tax adjustments: | ||||||||
Share-based compensation | 251 | 234 | ||||||
Upfront payments related to licenses and collaborations | 96 | 96 | ||||||
Acquired in-process research and development | (4 | ) | (4 | ) | ||||
Amortization of purchased intangible assets | 309 | 309 | ||||||
Change in fair value of contingent consideration | 12 | 12 | ||||||
Restructuring expenses | 20 | 20 | ||||||
Change in value of strategic equity investments | (21 | ) | (21 | ) | ||||
Adjustments to income tax expense | (257 | ) | (250 | ) | ||||
Non-GAAP net income | $ | 2,332 | $ | 2,366 | ||||
Diluted GAAP earnings per common share | $ | 8.58 | $ | 8.78 | ||||
Diluted non-GAAP earnings per common share | $ | 10.25 | $ | 10.40 |
Operating expense and margin (% total revenues) | ||||||
GAAP research and development expense | 18 | % | 17 | % | ||
Share-based compensation | 1 | % | 1 | % | ||
Upfront payments related to licenses and collaborations | 2 | % | 2 | % | ||
Non-GAAP research and development expense | 15 | % | 14 | % | ||
GAAP selling, general and administrative expense | 25 | % | 24 | % | ||
Share-based compensation | 3 | % | 3 | % | ||
Non-GAAP selling, general and administrative expense | 22 | % | 21 | % | ||
GAAP operating margin | 41 | % | 42 | % | ||
Share-based compensation | 5 | % | 5 | % | ||
Upfront payments related to licenses and collaborations | 2 | % | 2 | % | ||
Acquired in-process research and development | 0 | % | 0 | % | ||
Amortization of purchased intangible assets | 6 | % | 6 | % | ||
Change in fair value of contingent consideration | 0 | % | 0 | % | ||
Restructuring expenses | 0 | % | 0 | % | ||
Non-GAAP operating margin | 55 | % | 56 | % | ||
Income tax expense (% of income before income taxes) | ||||||
GAAP income tax expense | 6 | % | 5 | % | ||
Tax effect of pre-tax adjustments to GAAP net income and other one-time items associated with intellectual property | 8 | % | 8 | % | ||
Non-GAAP income tax expense | 14 | % | 13 | % |
Three months ended | Nine months ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2019 | 2018 | 2019 | 2018 | |||||||||||||
SOLIRIS | ||||||||||||||||
United States | $ | 496.8 | $ | 404.5 | $ | 1,456.8 | $ | 1,136.3 | ||||||||
Europe | 255.5 | 262.1 | 800.2 | 766.3 | ||||||||||||
Asia Pacific | 118.0 | 98.2 | 329.2 | 277.3 | ||||||||||||
Rest of World | 120.2 | 123.2 | 347.1 | 406.4 | ||||||||||||
Total Soliris | $ | 990.5 | $ | 888.0 | $ | 2,933.3 | $ | 2,586.3 | ||||||||
ULTOMIRIS | ||||||||||||||||
United States | $ | 65.1 | $ | — | $ | 143.9 | $ | — | ||||||||
Europe | 21.1 | — | 21.1 | — | ||||||||||||
Asia Pacific | 3.7 | — | 3.7 | — | ||||||||||||
Rest of World | — | — | — | — | ||||||||||||
Total Ultomiris | $ | 89.9 | $ | — | $ | 168.7 | $ | — | ||||||||
STRENSIQ | ||||||||||||||||
United States | $ | 118.0 | $ | 86.6 | $ | 323.7 | $ | 275.7 | ||||||||
Europe | 19.0 | 16.6 | 56.0 | 47.0 | ||||||||||||
Asia Pacific | 14.0 | 7.2 | 36.0 | 19.2 | ||||||||||||
Rest of World | 3.3 | 2.8 | 10.0 | 7.1 | ||||||||||||
Total Strensiq | $ | 154.3 | $ | 113.2 | $ | 425.7 | $ | 349.0 | ||||||||
KANUMA | ||||||||||||||||
United States | $ | 16.0 | $ | 13.7 | $ | 45.1 | $ | 38.6 | ||||||||
Europe | 6.3 | 4.7 | 19.4 | 16.4 | ||||||||||||
Asia Pacific | 1.3 | 0.8 | 3.4 | 2.9 | ||||||||||||
Rest of World | 4.8 | 6.1 | 10.2 | 8.4 | ||||||||||||
Total Kanuma | $ | 28.4 | $ | 25.3 | $ | 78.1 | $ | 66.3 | ||||||||
Net Product Sales | ||||||||||||||||
United States | $ | 695.9 | $ | 504.8 | $ | 1,969.5 | $ | 1,450.6 | ||||||||
Europe | 301.9 | 283.4 | 896.7 | 829.7 | ||||||||||||
Asia Pacific | 137.0 | 106.2 | 372.3 | 299.4 | ||||||||||||
Rest of World | 128.3 | 132.1 | 367.3 | 421.9 | ||||||||||||
Total Net Product Sales | $ | 1,263.1 | $ | 1,026.5 | $ | 3,605.8 | $ | 3,001.6 |
September 30, | December 31 | ||||||
2019 | 2018 | ||||||
Cash and cash equivalents | $ | 2,171.3 | $ | 1,365.5 | |||
Marketable securities | 44.4 | 198.3 | |||||
Trade accounts receivable, net | 1,116.3 | 922.3 | |||||
Inventories | 576.7 | 472.5 | |||||
Prepaid expenses and other current assets (1) | 432.5 | 426.4 | |||||
Property, plant and equipment, net (1) | 1,148.0 | 1,471.5 | |||||
Intangible assets, net | 3,410.1 | 3,641.3 | |||||
Goodwill | 5,037.4 | 5,037.4 | |||||
Right of use operating assets (1) | 206.9 | — | |||||
Other assets | 671.4 | 396.7 | |||||
Total assets | $ | 14,815.0 | $ | 13,931.9 | |||
Accounts payable and accrued expenses | $ | 868.2 | $ | 698.2 | |||
Revolving credit facility | — | 250.0 | |||||
Current portion of long-term debt | 126.6 | 93.8 | |||||
Current portion of contingent consideration | — | 97.6 | |||||
Other current liabilities (1) | 96.4 | 34.4 | |||||
Long-term debt, less current portion | 2,406.7 | 2,501.7 | |||||
Contingent consideration | 188.0 | 183.2 | |||||
Facility lease obligations (1) | — | 361.0 | |||||
Deferred tax liabilities | 314.7 | 391.1 | |||||
Noncurrent operating lease liabilities (1) | 166.8 | — | |||||
Other liabilities (1) | 280.4 | 155.6 | |||||
Total liabilities | 4,447.8 | 4,766.6 | |||||
Total stockholders' equity (1) | 10,367.2 | 9,165.3 | |||||
Total liabilities and stockholders' equity | $ | 14,815.0 | $ | 13,931.9 |
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end
Cover Page Statement |
Oct. 23, 2019 |
---|---|
Cover page. | |
Title of 12(g) Security | Common Stock, par value $0.0001 per share |
Entity Emerging Growth Company | false |
Written Communications | false |
Entity Incorporation, State or Country Code | DE |
Entity Central Index Key | 0000899866 |
Document Type | 8-K |
Document Period End Date | Oct. 23, 2019 |
Entity Registrant Name | ALEXION PHARMACEUTICALS, INC. |
Entity Address, Address Line One | 121 Seaport Boulevard |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02210 |
City Area Code | 475 |
Local Phone Number | 230-2596 |
Amendment Flag | false |
Entity File Number | 000-27756 |
Entity Tax Identification Number | 13-3648318 |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Trading Symbol | ALXN |
Security Exchange Name | NASDAQ |